These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 29995236

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S.
    J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
    [Abstract] [Full Text] [Related]

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Dec; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 5. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
    Yamamoto N, Tsurutani Y, Katsuragawa S, Kubo H, Sunouchi T, Hirose R, Hoshino Y, Ichikawa M, Takiguchi T, Yukawa H, Arioka H, Saitou J, Nishikawa T.
    Intern Med; 2019 Oct 01; 58(19):2825-2830. PubMed ID: 31243198
    [Abstract] [Full Text] [Related]

  • 6. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun 01; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 7. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Jun 01; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 8. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 01; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T.
    Cancer Med; 2019 Sep 01; 8(11):5183-5193. PubMed ID: 31353840
    [Abstract] [Full Text] [Related]

  • 12. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan 01; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
    Imai Y, Tanaka M, Fujii R, Uchitani K, Okazaki K.
    Yakugaku Zasshi; 2019 Jan 01; 139(3):491-495. PubMed ID: 30828027
    [Abstract] [Full Text] [Related]

  • 14. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH.
    J Cancer Res Clin Oncol; 2021 Aug 01; 147(8):2459-2469. PubMed ID: 33523301
    [Abstract] [Full Text] [Related]

  • 15. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 16. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.
    Ann Oncol; 2017 Jul 01; 28(7):1532-1539. PubMed ID: 28407039
    [Abstract] [Full Text] [Related]

  • 17. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M, Edahiro R, Krebe H, Nishida K, Ishijima M, Uenami T, Akazawa Y, Yano Y, Yamaguchi T, Mori M.
    Thorac Cancer; 2018 Dec 01; 9(12):1782-1787. PubMed ID: 30328672
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M, Sasaki S, Oikado K, Saito Y, Tominaga J, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K.
    Cancer Sci; 2021 Apr 01; 112(4):1506-1513. PubMed ID: 33125784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.